Lpath Scientists and Collaborators Present Favorable New Study Data of Leading Cancer Drug Candidate, ASONEP(TM)

DENVER, CO, Apr 20 (MARKET WIRE) --
Lpath, Inc. (OTCBB: LPTN), the category leader in
bioactive-lipid-targeted therapeutics, reported convincing
proof-of-principle data in a mouse model of renal cell carcinoma (RCC) for
it leading cancer drug candidate, ASONEP(TM), and provided a status update
of its ongoing Phase 1 clinical trial.

The RCC data were presented today by Rupal Bhatt, M.D., Ph.D. of the Beth
Israel Deaconess Medical Center (a major Harvard Medical School affiliate)
at the 100th Annual Meeting of the American Association for Cancer
Research ("AACR") in Denver, Colorado. Dr. Bhatt demonstrated that the
murine (or mouse) version of ASONEP, as a single agent in naive mice,
significantly delays the progression of disease. "The single-agent
results are encouraging and at least as good as what is often seen in
xenograft studies with VEGF-Receptor-Tyrosine-Kinase Inhibitors (TKIs),
the standard of care for treatment of RCC," said Bhatt.

Scott Pancoast, Lpath president and chief executive officer, commented,
"The results from this new study are exciting, as they suggest ASONEP
could be used to treat RCC as a single agent. The market potential of
such a scenario is substantial, given the two TKIs on the market --
Sutent(R) and Nexavar(R) -- generated 2008 revenues of over $1.5 billion,
a level that is growing rapidly."

Dr. Bhatt also presented evidence suggesting the pathway targeted by
ASONEP could be involved in resistance to TKI therapy. Nearly all RCC
patients treated with TKIs develop resistance and experience renewed
progression of disease with a "mean time to disease progression" of 1.9
months after initialization of TKI treatment. Moreover, agents approved
for dosing after TKI-therapy failure add another two months of
progression-free survival. As such, there is a great unmet need for
agents that will delay progression of renal cell cancer for longer
durations of time. According to Bhatt, "Lpath's ASONEP, which neutralizes
a tumorigenic pathway that is quite distinct from the VEGF pathway, holds
promise to further delay disease progression."

Dr. James Mier, also from Beth Israel Deaconess Medical Center and a
collaborator with Dr. Bhatt, said, "ASONEP has single agent activity in a
renal cancer xenograft model that looks as encouraging as the results
obtained with any of the available VEGF receptor antagonists."

A separate presentation at AACR was made by Dr. Roger Sabbadini, founder
and chief scientific officer of Lpath, who provided an update on the
ASONEP Phase 1 clinical trial in cancer. The ASONEP trial, which is
nearing completion, is testing the safety and tolerability of this
first-in-class anti-cancer agent. Dr. Sabbadini noted that investigators
have not reported any drug-related serious adverse events, even at the
higher doses, and Lpath is now focused on which cancer types to target in
its Phase 2 trials.

Lpath believes ASONEP could someday treat many of the deadliest solid and
liquid tumors. ASONEP binds to and inhibits the bioactive lipid
Sphingosine-1-Phosphate (S1P), which is a multifunctional mediator that
can become dysfunctional and contribute directly to the pathophysiology of
cancer.

About Lpath

Lpath, Inc., headquartered in San Diego, is the category leader in
bioactive-lipid-targeted therapeutics, an emerging field of medical
science whereby bioactive signaling lipids are targeted for treating
important human diseases. ASONEP(TM), an antibody against
Sphingosine-1-Phosphate (S1P), is currently in a Phase 1 clinical trial
in cancer and also holds promise against multiple sclerosis and various
other disorders. ASONEP is being developed with the support of partner
Merck-Serono as part of a worldwide exclusive license. A second product
candidate, iSONEP(TM) (the ocular formulation of the S1P antibody), has
demonstrated superior results in various preclinical models of
age-related macular degeneration (AMD) and retinopathy and is in a Phase
1 clinical trial in wet-AMD patients. Lpath's third product candidate,
Lpathomab(TM), is an antibody against Lysophosphatidic Acid (LPA), a key
bioactive lipid that has been long recognized as a valid disease target
(cancer, neuropathic pain, fibrosis). The company's unique ability to
generate novel antibodies against bioactive lipids is based on its
ImmuneY2(TM) drug-discovery engine, which the company is leveraging as a
means to expand its pipeline. For more information, go to www.Lpath.com

Lpath, Inc.
Scott R. Pancoast
(858) 678-0800 x104
President & CEO
Email Contact
www.Lpath.com

Lpath Investor Relations
Liolios Group, Inc.
(949) 574-3860
Geoffrey Plank: Email Contact
Ron Both: Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-